Change in Health Behaviors Affect Quality of Life in Lymphoma Survivors
Baseline alcohol consumption was associated with a higher QOL score compared with never use of alcohol.
Lymphoma
Serious Long-Term Adverse Events Decreased in Pediatric Hodgkin Lymphoma
A deepened understanding of long-term effects can help clinicians to better determine upfront therapy and monitoring strategies for pediatric patients with Hodgkin lymphoma.
Protocol for Nursing Care of Patients With Central Nervous System Lymphomas
This presentation discussed the key points of TEDDI-R protocol for managing the unique cluster of symptoms in patients with CNS lymphomas.
Prophylactic HD-MTX Does Not Improve CNS Relapse, Survival Outcomes in High-Risk DLBCL
A retrospective analysis was conducted to determine the safety and efficacy of high-dose methotrexate in patients with high-risk DLBCL.
Zynlonta Approved for Relapsed/Refractory Large B-Cell Lymphoma
Zynlonta (loncastuximab tesirine-lpyl) is a CD19-directed antibody and alkylating agent conjugate.
Engineered Cell Therapy AB-205 Shows Efficacy in Lymphoma With HDT-AHCT
Researchers sought to determine whether AB-205 would be a safe and effective therapy added to HDT-AHCT in adult patients with lymphoma.
Brentuximab Vedotin Shows Efficacy for Pediatric Patients With Classical Hodgkin Lymphoma
Researchers sought to determine the safety and efficacy of brentuximab vedotin in pediatric patients with classical Hodgkin lymphoma.
Hypomagnesemia at Time of Transplant Associated With Worse Survival in Patients With DLBCL
Researchers sought to determine whether hypomagnesemia increases the risk of failure for autologous hematopoietic stem cell transplantation in patients with DLBCL.
MATRix-RICE and Autologous HSCT Beneficial in DLBCL With CNS Involvement
Investigators report on findings from the MARIETTA study, which evaluated an intensive, CNS-directed chemoimmunotherapy followed by autoHSCT in patients with secondary CNS lymphoma.
Umbralisib Has Favorable Benefit-Risk Profile in Pretreated Patients With Indolent Non-Hodgkin Lymphoma
Investigators conducted a phase IIb study to assess the safety and efficacy of umbralisib 800 mg/d in patients with relapsed or refractory non-Hodgkin lymphoma.
-
Loading...
-
Loading...
Next post in Lymphoma
